» Articles » PMID: 35566714

Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 May 14
PMID 35566714
Authors
Affiliations
Soon will be listed here.
Abstract

Paraganglioma and pheochromocytoma are rare medical conditions. Thus, there are still a small number of studies, clinical trials, and evidence-based data in this field. This makes clinical decisions more difficult. In this study, we present a case report enriched with a short review of available essential clinical data, indicating the need for constant metoxycatecholamine level observation and a proper diagnostic imaging approach, especially in terms of ongoing pandemics. Our research also provides a summary of the molecular background of these diseases, indicating their future role in clinical management. We analyzed the ClinicalTrials.gov dataset in order to show future perspectives. In this paper, the use of the PET-CT before MRI or CT is proposed in specific cases during diagnosis processes contrary to the guidelines. PET-CT may be as effective as standard procedures and may provide a faster diagnosis, which is important in periods with more difficult access to health care, such as during the COVID-19 pandemic.

Citing Articles

F-FDG PET/CT and Ga-DOTATATE PET/CT Findings of Polycystic Kidney-derived Paraganglioma.

Tosunoglu Z, Baykal Koca S, Ergul N, Cermik T, Arsla E Mol Imaging Radionucl Ther. 2024; 33(3):182-184.

PMID: 39373189 PMC: 11589347. DOI: 10.4274/mirt.galenos.2024.03264.


Anesthetic Management of Robot-Assisted Laparoscopic Surgery of Pheochromocytoma.

Suryawanshi C, Varma S, Vazhakalayil S Cureus. 2024; 16(2):e53850.

PMID: 38465083 PMC: 10924627. DOI: 10.7759/cureus.53850.


Primary non-functional pancreatic paraganglioma: A case report and review of the literature.

Zhao Z, Guo Y, Liu L, Zhang L, Li S, Yang J J Int Med Res. 2022; 50(12):3000605221143023.

PMID: 36562124 PMC: 9793047. DOI: 10.1177/03000605221143023.


Neuroendocrine Tumors: Challenges and Future Perspectives.

Lamberti G, La Salvia A J Clin Med. 2022; 11(15).

PMID: 35955968 PMC: 9369270. DOI: 10.3390/jcm11154351.

References
1.
Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G . Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020; 4(5):e10-e11. PMC: 7146704. DOI: 10.1016/S2352-4642(20)30108-5. View

2.
Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B . Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology. 2019; 160(11):2600-2617. PMC: 6795182. DOI: 10.1210/en.2019-00410. View

3.
Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N . The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Front Endocrinol (Lausanne). 2020; 11:586857. PMC: 7732471. DOI: 10.3389/fendo.2020.586857. View

4.
Zitzmann K, von Ruden J, Brand S, Goke B, Lichtl J, Spottl G . Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 2010; 295(1):100-9. DOI: 10.1016/j.canlet.2010.02.018. View

5.
Lee S, Gross S, Pfaff H, Dresen A . Waiting time, communication quality, and patient satisfaction: An analysis of moderating influences on the relationship between perceived waiting time and the satisfaction of breast cancer patients during their inpatient stay. Patient Educ Couns. 2019; 103(4):819-825. DOI: 10.1016/j.pec.2019.11.018. View